{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:34:29Z","timestamp":1740123269093,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s10792-021-02044-0","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T12:04:52Z","timestamp":1641470692000},"page":"785-797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Testing the eligibility of glaucoma patients for potential gene therapy among a clinic population"],"prefix":"10.1007","volume":"42","author":[{"given":"Carmen","family":"Gruzei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jufen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-1645","authenticated-orcid":false,"given":"Rupert","family":"Bourne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"2044_CR1","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study (2021) Causes of blindness and\u00a0vision\u00a0impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to\u00a0VISION\u00a02020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health 9(2):e144\u2013e160"},{"issue":"11","key":"2044_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121(11):2081\u20132090. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.013","journal-title":"Ophthalmology"},{"issue":"10","key":"2044_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162229","volume":"11","author":"RR Bourne","year":"2016","unstructured":"Bourne RR, Taylor HR, Flaxman SR, Keeffe J, Leasher J, Naidoo K, Pesudovs K, White RA, Wong TY, Resnikoff S, Jonas JB (2016) Number of people blind or visually impaired by Glaucoma worldwide and in World Regions 1990\u20132010: a meta-analysis. PLoS ONE 11(10):e0162229. https:\/\/doi.org\/10.1371\/journal.pone.0162229","journal-title":"PLoS ONE"},{"issue":"1","key":"2044_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1120672120960339","volume":"31","author":"MD Toro","year":"2021","unstructured":"Toro MD, Br\u00e9zin AP, Burdon M, Cummings AB, Evren Kemer O, Malyugin BE, Prieto I, Teus MA, Tognetto D, T\u00f6rnblom R, Posarelli C, Chor\u0105giewicz T, Rejdak R (2021) Early impact of COVID-19 outbreak on eye care: Insights from EUROCOVCAT group. Eur J Ophthalmol 31(1):5\u20139. https:\/\/doi.org\/10.1177\/1120672120960339","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"2044_CR5","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/archophthalmol.2011.72","volume":"129","author":"CG De Moraes","year":"2011","unstructured":"De Moraes CG, Juthani VJ, Liebmann JM, Teng CC, Tello C, Susanna R Jr, Ritch R (2011) Risk factors for visual field progression in treated glaucoma. Arch Ophthalmol 129(5):562\u2013568. https:\/\/doi.org\/10.1001\/archophthalmol.2011.72","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"2044_CR6","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/eye.2011.33","volume":"25","author":"I Forchheimer","year":"2011","unstructured":"Forchheimer I, de Moraes CG, Teng CC, Folgar F, Tello C, Ritch R, Liebmann JM (2011) Baseline mean deviation and rates of visual field change in treated glaucoma patients. Eye (Lond) 25(5):626\u2013632. https:\/\/doi.org\/10.1038\/eye.2011.33","journal-title":"Eye (Lond)"},{"issue":"5","key":"2044_CR7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1755-3768.2012.02492.x","volume":"91","author":"A Heijl","year":"2013","unstructured":"Heijl A, Buchholz P, Norrgren G, Bengtsson B (2013) Rates of visual field progression in clinical glaucoma care. Acta Ophthalmol 91(5):406\u2013412. https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02492.x","journal-title":"Acta Ophthalmol"},{"key":"2044_CR8","doi-asserted-by":"publisher","unstructured":"Chauhan BC, Mikelberg FS, Artes PH, Balazsi AG, LeBlanc RP, Lesk MR, Nicolela MT, Trope GE (2010) Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol 128 (10):1249\u20131255. https:\/\/doi.org\/10.1001\/archophthalmol.2010.196","DOI":"10.1001\/archophthalmol.2010.196"},{"issue":"7","key":"2044_CR9","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1167\/iovs.14-14643","volume":"55","author":"BC Chauhan","year":"2014","unstructured":"Chauhan BC, Malik R, Shuba LM, Rafuse PE, Nicolela MT, Artes PH (2014) Rates of glaucomatous visual field change in a large clinical population. Invest Ophthalmol Vis Sci 55(7):4135\u20134143. https:\/\/doi.org\/10.1167\/iovs.14-14643","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"2044_CR10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/eye.2013.294","volume":"28","author":"JF Kirwan","year":"2014","unstructured":"Kirwan JF, Hustler A, Bobat H, Toms L, Crabb DP, McNaught AI (2014) Portsmouth visual field database: an audit of glaucoma progression. Eye (Lond) 28(8):974\u2013979. https:\/\/doi.org\/10.1038\/eye.2013.294","journal-title":"Eye (Lond)"},{"issue":"1","key":"2044_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1167\/iovs.13-13006","volume":"55","author":"LJ Saunders","year":"2014","unstructured":"Saunders LJ, Russell RA, Kirwan JF, McNaught AI, Crabb DP (2014) Examining visual field loss in patients in Glaucoma clinics during their predicted remaining lifetime predicted lifetime visual field loss in glaucoma. Invest Ophthalmol Vis Sci 55(1):102\u2013109. https:\/\/doi.org\/10.1167\/iovs.13-13006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"2044_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1755-3768.2011.02260.x","volume":"91","author":"CG De Moraes","year":"2013","unstructured":"De Moraes CG, Liebmann JM, Liebmann CA, Susanna R Jr, Tello C, Ritch R (2013) Visual field progression outcomes in glaucoma subtypes. Acta Ophthalmol 91(3):288\u2013293. https:\/\/doi.org\/10.1111\/j.1755-3768.2011.02260.x","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"2044_CR13","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00417-016-3321-2","volume":"254","author":"M Waisbourd","year":"2016","unstructured":"Waisbourd M, Ahmed OM, Molineaux J, Gonzalez A, Spaeth GL, Katz LJ (2016) Reversible structural and functional changes after intraocular pressure reduction in patients with glaucoma. Graefes Arch Clin Exp Ophthalmol 254(6):1159\u20131166. https:\/\/doi.org\/10.1007\/s00417-016-3321-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2044_CR14","doi-asserted-by":"publisher","first-page":"9890831","DOI":"10.1155\/2019\/9890831","volume":"2019","author":"C Posarelli","year":"2019","unstructured":"Posarelli C, Ortenzio P, Ferreras A, Toro MD, Passani A, Loiudice P, Oddone F, Casini G, Figus M (2019) Twenty-four-hour contact lens sensor monitoring of aqueous humor dynamics in surgically or medically treated glaucoma patients. J Ophthalmol 2019:9890831. https:\/\/doi.org\/10.1155\/2019\/9890831","journal-title":"J Ophthalmol"},{"key":"2044_CR15","doi-asserted-by":"publisher","unstructured":"Posarelli C, Toro MD, Rejdak R, \u017barnowski T, Po\u017carowska D, Longo A, Miccoli M, Nardi M, Figus M (2020) Safety and efficacy of second Ahmed valve implant in refractory glaucoma. J Clin Med 9 (7). https:\/\/doi.org\/10.3390\/jcm9072039","DOI":"10.3390\/jcm9072039"},{"issue":"12","key":"2044_CR16","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/s2214-109x(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR (2017) Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Health 5(12):e1221\u2013e1234. https:\/\/doi.org\/10.1016\/s2214-109x(17)30393-5","journal-title":"Lancet Glob Health"},{"issue":"10","key":"2044_CR17","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41419-018-1041-8","volume":"9","author":"A Osborne","year":"2018","unstructured":"Osborne A, Khatib TZ, Songra L, Barber AC, Hall K, Kong GYX, Widdowson PS, Martin KR (2018) Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor\/tropomyosin-related kinase receptor-B signaling. Cell Death Dis 9(10):1007. https:\/\/doi.org\/10.1038\/s41419-018-1041-8","journal-title":"Cell Death Dis"},{"key":"2044_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.573238","volume":"11","author":"M Fiedorowicz","year":"2020","unstructured":"Fiedorowicz M, We\u0142niak-Kami\u0144ska M, \u015awi\u0105tkiewicz M, Orze\u0142 J, Chor\u0105giewicz T, Toro MD, Rejdak R, Bogorodzki P, Grieb P (2020) Changes of ocular dimensions as a marker of disease progression in a Murine model of pigmentary glaucoma. Front Pharmacol 11:573238. https:\/\/doi.org\/10.3389\/fphar.2020.573238","journal-title":"Front Pharmacol"},{"key":"2044_CR19","doi-asserted-by":"publisher","unstructured":"Kami\u0144ska A, Romano GL, Rejdak R, Zweifel S, Fiedorowicz M, Rejdak M, Bajka A, Amato R, Bucolo C, Avitabile T, Drago F, Toro MD (2021) Influence of trace elements on neurodegenerative diseases of the eye-The Glaucoma Model. Int J Mol Sci 22 (9). https:\/\/doi.org\/10.3390\/ijms22094323","DOI":"10.3390\/ijms22094323"},{"issue":"18","key":"2044_CR20","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA (2014) The pathophysiology and treatment of glaucoma: a review. JAMA 311(18):1901\u20131911. https:\/\/doi.org\/10.1001\/jama.2014.3192","journal-title":"JAMA"},{"key":"2044_CR21","doi-asserted-by":"publisher","unstructured":"Fiedorowicz M, Choragiewicz T, Turski WA, Kocki T, Nowakowska D, Wertejuk K, Kami\u0144ska A, Avitabile T, We\u0142niak-Kaminska M, Grieb P, Zweifel S, Rejdak R, Toro MD (2021) Tryptophan pathway abnormalities in a murine model of hereditary glaucoma. Int J Mol Sci 22 (3). https:\/\/doi.org\/10.3390\/ijms22031039","DOI":"10.3390\/ijms22031039"},{"issue":"9","key":"2044_CR22","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ophtha.2004.02.017","volume":"111","author":"K Nouri-Mahdavi","year":"2004","unstructured":"Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, Caprioli J (2004) Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 111(9):1627\u20131635. https:\/\/doi.org\/10.1016\/j.ophtha.2004.02.017","journal-title":"Ophthalmology"},{"key":"2044_CR23","doi-asserted-by":"publisher","unstructured":"Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk MR, Trope GE (2008) Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 126 (8):1030\u20131036. https:\/\/doi.org\/10.1001\/archopht.126.8.1030","DOI":"10.1001\/archopht.126.8.1030"},{"issue":"9","key":"2044_CR24","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1001\/archophthalmol.2009.165","volume":"127","author":"CG De Moraes","year":"2009","unstructured":"De Moraes CG, Prata TS, Tello C, Ritch R, Liebmann JM (2009) Glaucoma with early visual field loss affecting both hemifields and the risk of disease progression. Arch Ophthalmol 127(9):1129\u20131134. https:\/\/doi.org\/10.1001\/archophthalmol.2009.165","journal-title":"Arch Ophthalmol"},{"key":"2044_CR25","doi-asserted-by":"crossref","unstructured":"Ederer F, Gaasterland DE, Sullivan EK (1994) The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials 15 (4):299\u2013325","DOI":"10.1016\/0197-2456(94)90046-9"},{"issue":"1","key":"2044_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ophtha.2012.07.028","volume":"120","author":"DF Garway-Heath","year":"2013","unstructured":"Garway-Heath DF, Lascaratos G, Bunce C, Crabb DP, Russell RA, Shah A (2013) The United Kingdom Glaucoma Treatment Study: a multicenter, randomized, placebo-controlled clinical trial: design and methodology. Ophthalmology 120(1):68\u201376. https:\/\/doi.org\/10.1016\/j.ophtha.2012.07.028","journal-title":"Ophthalmology"},{"issue":"1","key":"2044_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/archopht.1996.01100130017003","volume":"114","author":"A Heijl","year":"1996","unstructured":"Heijl A, Bengtsson B (1996) The effect of perimetric experience in patients with glaucoma. Arch Ophthalmol 114(1):19\u201322. https:\/\/doi.org\/10.1001\/archopht.1996.01100130017003","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"2044_CR28","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/S0161-6420(01)00799-0","volume":"108","author":"LM Weih","year":"2001","unstructured":"Weih LM, Nanjan M, McCarty CA, Taylor HR (2001) Prevalence and predictors of open-angle glaucoma: Results from the visual impairment project. Ophthalmology 108(11):1966\u20131972. https:\/\/doi.org\/10.1016\/S0161-6420(01)00799-0","journal-title":"Ophthalmology"},{"issue":"8","key":"2044_CR29","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1136\/bjo.2004.062927","volume":"89","author":"BC Chauhan","year":"2005","unstructured":"Chauhan BC, Hutchison DM, LeBlanc RP, Artes PH, Nicolela MT (2005) Central corneal thickness and progression of the visual field and optic disc in glaucoma. Br J Ophthalmol 89(8):1008\u20131012. https:\/\/doi.org\/10.1136\/bjo.2004.062927","journal-title":"Br J Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02044-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-021-02044-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02044-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T16:50:16Z","timestamp":1647017416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-021-02044-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2044"],"URL":"https:\/\/doi.org\/10.1007\/s10792-021-02044-0","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"type":"print","value":"0165-5701"},{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"19 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The retrospective chart review was approved as a Service Evaluation by the Department of Patient Safety at Cambridge University Hospital, United Kingdom. Informed consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}